Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Overactive Bladder Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility of Parasacral Transcutaneous Electrical Nerve Stimulation PTENS for Voiding Dysfunction in Peds Population

NCT04570605
View directory record Official record
Conditions
Overactive Bladder, Voiding Disorders, Incontinence, Urinary
Interventions
parasacral transcutaneous electrical nerve stimulation (PTENS), Standard Urotherapy
Device · Other
Lead sponsor
University of Utah
Other
Eligibility
6 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Jul 21, 2026, 6:11 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy

NCT07175805
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Stress Urinary Incontinence, Urge Urinary Incontinence, Overactive Bladder, Pelvic Organ Prolapse, Weight Loss, Fecal Incontinence, Bariatric Surgery, glp1 Agonist
Interventions
Bariatric Surgery, GLP1 receptor agonist
Procedure · Drug
Lead sponsor
Hartford HealthCare
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 21, 2026, 6:11 PM EDT
Terminated Not applicable Interventional

Group Medical Visits for Latina Women With Urgency Urinary Incontinence

NCT03687164
View directory record Official record
Conditions
Overactive Bladder, Urinary Urgency, Urge Incontinence
Interventions
Group Medical Visits
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder

NCT00501267
View directory record Official record
Conditions
Overactive Bladder
Interventions
solabegron and oxybutynin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Not applicable Interventional

Fluids Affecting Bladder Urgency and Lower Urinary Symptoms

NCT03625492
View directory record Official record
Conditions
Overactive Bladder, Urinary Urgency, Urinary Bladder, Overactive, Urinary Incontinence, Urge, Caffeine, Alcohol Drinking, Lower Urinary Tract Symptoms
Interventions
Reducing Potentially Irritating Beverages, Adopting the USDA Healthy Eating Habits
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Results available

Overactive Bladder Innovative Therapy Trial (OrBIT)

NCT00448175
View directory record Official record
Conditions
Overactive Bladder
Interventions
Urgent PC Neuromodulation System, Tolterodine
Device · Drug
Lead sponsor
Uroplasty, Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minnetonka, Minnesota
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Results available

Procedural Discomfort Related to Number of Intradetrusor Botox Injections

NCT05652036
View directory record Official record
Conditions
Overactive Bladder
Interventions
Intradetrusor Botox Injections
Biological
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Jul 21, 2026, 6:11 PM EDT
Completed No phase listed Observational

The Urinary Microbiome in Patients Receiving Intradetrusor Botox Injections

NCT04479709
View directory record Official record
Conditions
Overactive Bladder
Interventions
Not listed
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
60 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Results available

A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.

NCT01302054
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Fesoterodine 8 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
109
States / cities
Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Jul 21, 2026, 6:11 PM EDT
Completed No phase listed Observational

Combined Anticholinergic Medication and Sacral Neuromodulation to Treat Refractory Overactive Bladder

NCT01047046
View directory record Official record
Conditions
Overactive Bladder
Interventions
Retrospective chart review
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2010 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Results available

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder

NCT02045862
View directory record Official record
Conditions
Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
Interventions
Solifenacin succinate, Mirabegron, Placebo to match solifenacin, Placebo to match mirabegron
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years and older
Enrollment
1,829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
75
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Jul 21, 2026, 6:11 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effect of an Additional Stress Incontinence Procedure on Overactive Bladder During Pelvic Organ Prolapse Repair

NCT02502838
View directory record Official record
Conditions
Overactive Bladder, Pelvic Organ Prolapse
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
22 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 1 Interventional

Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function

NCT04454424
View directory record Official record
Conditions
Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions
BAY1817080, Midazolam
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Not applicable Interventional Results available

eCoin for OAB Feasibility Follow-on Study

NCT03655054
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
Interventions
eCoin Tibial Nerve Stimulation
Device
Lead sponsor
Valencia Technologies Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Newport Beach, California • Waterloo, Iowa • Greensboro, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Results available

Trospium Chloride XR in Obese Female Patients With Overactive Bladder

NCT00932022
View directory record Official record
Conditions
Obesity, Overactive Bladder, Incontinence
Interventions
Trospium Chloride, Extended Release (XR), placebo
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
La Mesa, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2013 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Results available

Fesoterodine Flexible Dose Study

NCT00536484
View directory record Official record
Conditions
Overactive Bladder
Interventions
Fesoterodine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
896 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
95
States / cities
Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2009 · Synced Jul 21, 2026, 6:11 PM EDT
Recruiting Phase 3 Interventional

Oxybutynin for Post-surgical Bladder Pain and Urgency

NCT03952299
View directory record Official record
Conditions
Overactive Bladder Syndrome, Neuropathic Bladder
Interventions
Oxybutynin Transdermal Patch, Oral Oxybutynin
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
4 Years to 8 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Not applicable Interventional

Urodynamic Testing: Can we Improve Patient Experience?

NCT02742389
View directory record Official record
Conditions
Urinary Incontinence, Urinary Bladder, Overactive, Lower Urinary Tract Symptoms
Interventions
Preprocedure Telephone Call
Other
Lead sponsor
Boston Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

NCT02757768
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Overactive Bladder
Interventions
Mirabegron, Placebo, Tamsulosin Hydrochloride
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
32
States / cities
Homewood, Alabama • Huntsville, Alabama • Anchorage, Alaska + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Jul 21, 2026, 6:11 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical and Biochemical Evidence of Neurogenic Inflammation in Women With Urinary Urgency

NCT01933074
View directory record Official record
Conditions
Overactive Bladder
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Jul 21, 2026, 6:11 PM EDT
Recruiting Not applicable Interventional

A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)

NCT05685433
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
Interventions
eCoin Tibial Nerve Stimulation
Device
Lead sponsor
Valencia Technologies Corporation
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
22
States / cities
Homewood, Alabama • Mobile, Alabama • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Results available

Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

NCT00910520
View directory record Official record
Conditions
Overactive Bladder
Interventions
onabotulinumtoxinA, normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Results available

Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.

NCT04534491
View directory record Official record
Conditions
Overactive Bladder
Interventions
Oxybutynin (Oxytrol, BAY839380)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Saint Joseph, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 4 Interventional

Lidocaine for Pain After Urodynamic Testing

NCT03390790
View directory record Official record
Conditions
Voiding Disorders, Overactive Bladder, Urinary Incontinence
Interventions
Lidocaine gel 2%, Standard lubricant gel
Drug · Other
Lead sponsor
Atlantic Health System
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Jul 21, 2026, 6:11 PM EDT